Related Experiment Video
Updated: Aug 18, 2026

Modified Annexin V/Propidium Iodide Apoptosis Assay For Accurate Assessment of Cell Death
Published on: April 24, 2011
Imaging apoptosis in vivo using 124I-annexin V and PET
Heather G Keen1, Bronwen A Dekker, Lynn Disley
1Cancer Research UK Department of Radiochemical Targeting and Imaging, Paterson Institute for Cancer Research, Christie Hospital NHS Trust, M20 4BX Manchester, UK.
Abstract:
Abnormal regulation of apoptosis is an important pathogenic mechanism in many diseases including cancer. Techniques to assess apoptosis in living organisms are limited and, in the case of solid organs, restricted to histological examination of biopsy samples. We investigated the use of (124)I-annexin V, which binds to phosphatidylserine (PS) on the surface of apoptotic cells, as a potential positron emission tomography (PET) radioligand for the noninvasive measurement of apoptosis in vivo. Annexin V and a similar-sized protein, ovalbumin, were directly labelled with (124)I. We report the validation of (124)I-annexin V in vitro and in an animal model of liver apoptosis that has not previously been used to test iodinated annexin V. Also, for the first time, we report metabolite analysis of (124)I-annexin V and the correlation of (124)I-annexin V uptake with apoptotic density (AD). Sixfold more (124)I-annexin V was associated with Jurkat cells after apoptosis induction, indicating that PS binding by annexin V was preserved after iodination. (124)I-ovalbumin did not demonstrate increased uptake in apoptotic cells. In normal BDF-1 mice, the radioligand was rapidly cleared, but some in vivo dehalogenation resulted in the accumulation of activity in the thyroid and stomach content. PET images demonstrated uptake of (124)I-annexin V but not (124)I-ovalbumin in apoptotic liver lesions. In vivo (124)I-annexin V uptake, derived from PET images, correlated with histologically derived AD (r=.86, P<.01). These results demonstrate that (124)I-annexin V is localised to anti-Fas-induced apoptosis, in contrast to (124)I-ovalbumin, which did not show preferential uptake in the apoptotic liver.
Insights
We developed (124)I-annexin V as a novel imaging agent to detect apoptosis, or programmed cell death, in vivo. This positron emission tomography (PET) radioligand shows promise for noninvasively measuring apoptosis in diseases like cancer.
Area of Science:
- Nuclear Medicine
- Molecular Imaging
- Cell Biology
Background:
- Abnormal apoptosis regulation is key in diseases such as cancer.
- Current methods for assessing apoptosis in solid organs are invasive, relying on histology of biopsy samples.
- Noninvasive imaging techniques for apoptosis are limited.
Purpose of the Study:
- To investigate (124)I-annexin V as a positron emission tomography (PET) radioligand for noninvasive in vivo apoptosis measurement.
- To validate (124)I-annexin V in vitro and in an animal model of liver apoptosis.
- To assess metabolite analysis and correlate (124)I-annexin V uptake with apoptotic density (AD).
Main Methods:
- Direct labeling of annexin V and ovalbumin with iodine-124 ((124)I).
- In vitro validation using Jurkat cells and in vivo studies in a mouse model of liver apoptosis.
- Positron emission tomography (PET) imaging and histological assessment of apoptotic density (AD).
Main Results:
- Iodinated annexin V retained phosphatidylserine (PS) binding, with sixfold higher association with apoptotic cells.
- (124)I-ovalbumin did not show increased uptake in apoptotic cells.
- PET imaging revealed (124)I-annexin V uptake in apoptotic liver lesions, correlating strongly with histological AD (r=.86, P<.01).
- In vivo dehalogenation of (124)I-annexin V occurred, leading to thyroid and stomach accumulation.
Conclusions:
- (124)I-annexin V effectively localizes to sites of apoptosis in vivo.
- This radioligand demonstrates potential for noninvasive assessment of apoptosis using PET imaging.
- Further research may explore its utility in various disease states characterized by abnormal apoptosis.

